Calypte Files Registration Statement Registering Primarily Previously Issued Shares ALAMEDA, Calif., June 16 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC:CYPT) (BULLETIN BOARD: CYPT) , a developer, manufacturer and marketer of HIV diagnostic tests, today announced that it has filed a registration statement (the "Registration Statement") with the Securities and Exchange Commission registering shares of common stock purchased and shares of common stock underlying warrants purchased in its recent private placement (the "May 2004 PIPE"), as well as other unregistered shares of common stock, primarily owned by Marr Technologies BV, an affiliate of Calypte and its largest stockholder. Calypte currently has approximately 164 million shares of common stock issued and outstanding, which includes approximately 71 million of the shares being registered pursuant to the Registration Statement. These shares being registered represent approximately 43% of the Company's currently issued and outstanding common stock. Of the 71 million shares, approximately 51 million are owned by affiliates of Calypte, and the balance by investors in the May 2004 PIPE other than affiliates of Calypte and other financings, as well as vendors and consultants who have received common stock in lieu of cash. The Registration Statement provides for the issuance of an additional 12 million shares, which includes approximately 9 million shares to be held for issuance upon exercise of the warrants issued in the May 2004 PIPE. Affiliates of Calypte hold about 70% of those warrants. About Calypte Biomedical: Calypte Biomedical Corporation, headquartered in Northern California, is a public healthcare company dedicated to the development and commercialization of in vitro diagnostic tests, primarily for the detection of antibodies to Human Immunodeficiency Virus (HIV), and other sexually transmitted and infectious diseases. Calypte's currently marketed laboratory-based tests include an enzyme immunoassay (EIA) HIV-1 antibody screening test and an HIV-1 antibody western blot supplemental test, the only two FDA-approved HIV-1 antibody tests for use on urine samples, as well as an FDA-approved serum HIV-1 antibody western blot supplemental test. Calypte is actively engaged in developing new test products for the rapid detection of HIV and other infectious diseases. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser-developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other infectious diseases may make important contributions to public health. Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2003 and its subsequent filings with the SEC. Company Contact: Investor Relations Contact: Richard Brounstein, CFO Tim Clemensen, (510) 749-5100 Rubenstein Investor Relations email: Phone: 212-843-9337 Email: DATASOURCE: Calypte Biomedical Corporation CONTACT: Richard Brounstein, CFO, +1-510-749-5100, ; Tim Clemensen, Rubenstein Investor Relations, +1-212-843-9337, , for Calypte Biomedical Corporation Web site: http://www.calypte.com/

Copyright